Supplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study — Donald P. Cameron (2023) | RDL Network
Supplementary Methods from First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Preprint 2023 en
Authors
DC
Donald P. Cameron
NH
Nadine Hein
KM
Kylee Maclachlan
Abstract
1 min read
<p>All Supplementary Methods and associated references</p>
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Amit Khot, Natalie Brajanovski, Donald P. Cameron, Nadine Hein, Kylee Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R. Thompson, Andrew Fellowes, Karen E. Sheppard, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan, Gretchen Poortinga, Simon J. Harrison
Discussion(0)
No comments yet. Be the first to comment.